Primary and secondary prevention of thromboembolic events in atrial fibrillation

O.I. Dyadyk, L.S. Kholopov, O.V. Shchukina, N.O. Prokopenko, O.Y. Zaitseva, K.I. Chernyaeva

References

1. Пархоменко А.Н. Риск развития тромбоэмболических осложнений у больных с мерцательной аритмией и применение антикоагулянтов и антиагрегантов для профилактики инсульта // Укр. кардіол. журн.– 2002.– Додаток 2.– С. 4–14.
2. Дзяк Г.В., Васильева Л.И., Сапожниченко Л.В. и др. Антикоагулянты непрямого действия в кардиологии: показания и противопоказания, дозирование и осложнения // Ліки України.– 2009.– № 7.– С. 115–121.
3. Alexander J.H., Becker R.C., Bhatt D.L. et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial // Circulation. – 2009.– Vol. 19, № 22.– P. 2877–2885. 
4. Alexander J.H., Lopes R.D., James S. et al. Apixaban with antiplatelet therapy after acute coronary syndrome // N. Engl. J. Med.– 2011.– Vol. 365.– P. 699–708.
5. Artang R., Rome E., Nielsen J.D., Vidaillet H.J. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors [електронний ресурс] // Amer. J. Cardiol. – 2013.– Режим доступу до журн.: http:// www. pii: S0002-9149(13)01709-8. 
6. Bassand J.P. Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents // Europace.– 2012.– Vol. 14.– P. 312–324.
7. Beasley B.N., Unger E.F., Temple R. Anticoagulant options — why the FDA approved a higher but not a lower dose of dabigatran // N. Engl. J. Med.– 2011.– Vol. 364.– P. 1788–1790.
8. Becker R., Berkowitz S.D., Breithardt G. et al. Rivaroxaban – once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study // Amer. Heart J.– 2010.– Vol. 159.– P. 340–347. 
9. Bogatkevich G.S., Ludwicka-Bradley А., Silver R. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts // J. Arthritis Rheum.– 2009.– Vol. 60.– P. 3455–3464. 
10. Büller H.R., Halperin J.L., Bounameaux H. et al. Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants // J. Thromb. Haemost.– 2008.– Vol. 6.– P. 227–229.
11. Camm A.J., Lip G.Y.H., Caterina R. et al. Guidelines for the management of atrial fibrillation // Eur. Heart J.– 2012.– Vol. 33.– P. 2719–2747.
12. Cid-Conde L., Lopez-Castro J. New oral anticoagulants in atrial fibrillation // Atrial fibrillation – Mechanisms and Treatment / Ed. by Tong Liu.– InTech, 2013.– Ch.9.– P. 207–238.
13. Cohen A.T., Spiro T.E., Büller H.R. et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients // New Engl. J. Med.– 2013.– Vol. 368.– P. 513–523.
14. Connolly S., Pogue J., Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial // Lancet.– 2006.– Vol. 367.– P. 1903–1912.
15. Connolly S.J., Eikelboom J., Joyner C. et al. Apixaban in patients with atrial fibrillation // New Engl. J. Med.– 2011.– Vol. 364.– P. 806–817.
16. Connolly S.J., Wallentin L., Ezekowitz M.D. et al. The long term multi-center observational study of dabigatran treatment in patients with atrial fibrillation: (RELY-ABLE) study // Circulation.– 2013.– Vol. 128.– P. 237–243.
17. Connolly S.J., Pogue J., Hart R.G. et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation // N. Engl. J. Med.– 2009.– Vol. 360.– P. 2066–2078.
18. Coppens M., Eikelboom J.W., Hart R.G. et al. The score identifies those patients with atrial fibrillation CHA2DS2-VASc and CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy // Eur. Heart J.– 2013.– Vol. 34.– P. 170–176.
19. Eikelboom J.W., O'Donnell M., Yusuf S. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment // Amer. Heart J.– 2010.– Vol. 159.– P. 348–353.
20. Erdoran O. Risk assessment and therapy decision in patients at low risk for stroke: CHA2DS2-VASc vs CHADS2 // Eur. Heart J.– 2013.– Vol. 34.– P. 168–169.
21. Eriksson B.I., Borris L.C., Friedman R.J. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty // New Engl. J. Med.– 2008.– Vol. 358.– P. 2765–2775.
22. Eriksson B.I., Dahl O.E., Huo M.H. et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial // Thromb. Haemost. – 2011.– Vol. 105, № 4.– P. 721–729. 
23. Eriksson B.I., Dahl O.E., Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial // Lancet.– 2007.– Vol. 370.– P. 949–956. 
24. Eriksson B.I., Dahl O.E., Rosencher N. et al. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial // J. Thromb. Haemost.– 2007.– Vol. 5.– P. 2178–2185.
25. Evidence-Based Management of Anticoagulant Therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians. Evidence-Based Clinical Practice Guidelines // Chest.– 2012.– Vol. 141 (Suppl. 2).– P. e152S–e184S.
26. Ezekowitz M.D., Connolly S., Parekh A. et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran // Amer. Heart J.– 2009.– Vol. 157.– P. 805–810. 
27. Ezekowitz M.D., Reilly P. A., Nehmiz G. et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study) // Amer. J. Cardiol.– 2007.– Vol. 100.– P. 1419–1426.
28. Fanikos J.R., Atay J.K., Connors J.M. Improving anticoagulation management in patients with atrial fibrillation // Pharm. Ther.– 2013.– Vol. 38, № 3.– P. 173–177.
29. Fox K.A.A., Piccini J.P. , Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment // Eur. Heart J.– 2011.– Vol. 32.– P. 2387–2394.
30. Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation // Eur. Heart J.– 2010.– Vol. 31.– P. 967–975.
31. Friedman R.J. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials // Orthopedics.– 2011.– Vol. 34, № 10.– P. 795–804. 
32. Fu R., Wu S., Wu P. et al. A study of blood soluble P-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation // Europace.– 2011.– Vol. 13.– P. 31–36.
33. Galal Azzam H.A. Thrombogenesis in atrial fibrillation // Atrial Fibrillation – Mechanisms and Treatment / Ed. by Tong Liu.– InTech, 2013.– Сh.6.– P. 127–151.
34. Gerotziafas G.T., Elalamy I., Depasse F. et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban // J. Thromb. Haemost.– 2007.– Vol. 5.– P. 886–888.
35. Ginsberg J.S., Davidson B.L., Comp P. C. et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery // J. Arthroplasty. – 2009.– Vol. 24, № 1.– P. 1–9.
36. Go A.S., Fang M.C., Udaltsova N. et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation. The anticoagulation and risk factors in atrial fibrillation (ATRIA) study // Circulation.– 2009.– Vol. 119.– P. 1363–1369.
37. Go A.S., Hylek E.M., Chang Y. et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? // J. Amer. Med. Assoc.– 2003.– Vol. 290.– P. 2685–2692.
38. Goldhaber S.Z., Leizorovicz A., Kakkar A.K. et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients // New Engl. J. Med.– 2011.– Vol. 365.– P. 2167–2177.
39. Granger C.B., Alexander J.H., McMurray J.J.V. et al. Apixaban versus warfarin in patients with atrial fibrillation // N. Engl. J. Med.– 2011.– Vol. 365.– P. 981–992.
40. Guyatt G.H., Akl E.A., Crowther M. et al. Antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Executive summary // Chest.– 2012.– Vol. 141 (Suppl. 2).– P. 7–47.
41. Haris M., Usman U., Notaro L.A. et al. New developments in anticoagulation for atrial fibrillation // Curr. Treatment Options Cardiovasc. Med.– 2008.– Vol. 10.– P. 388–397.
42. Hart R.G., Eikelboom J.W., Ingram A.J. et al. Anticoagulants in atrial fibrillation patients with chronic kidney disease // Nat. Rev. Nephrol.– 2012.– Vol. 8.– P. 569–578.
43. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation // Ann. Intern. Med.– 2007.– Vol. 146.– P. 857–867.
44. Healey J.S., Eikelboom J., Wallentin L. et al. Effect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: an analysis from the RELY study // J. Amer. Coll. Cardiol.– 2010.– Vol. 55 (Suppl.10).– P. 4–37.
45. Heidbuchel H., Verhamme P., Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation // Europace.– 2013.– Vol. 15.– P. 625–651.
46. Hohnloser S.H., Connolly S.J. Atrial fibrillation, moderate chronic kidney disease, and stroke prevention: new anticoagulants, new hope // Eur. Heart J.– 2011.– Vol. 32.– P. 2347–2349.
47. Hughes M., Lip G.Y.H. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk stratification schema and cost effectiveness data // Thrombosis and Haemostasis.– 2008.– Vol. 99.– P. 295–304.
48. Hylek E.M. Therapeutic potential of oral factor Xa inhibitors // New Engl. J. Med.– 2010.– Vol. 363.– P. 2559–2561.
49. Koti M.J., Parekh A., Connolly S.J. et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion // J. Amer. Coll. Cardiol.– 2010.– Vol. 55 (Suppl.10).– P. 4–40.
50. Kubitza D., Becka M., Mueck W. et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban – an oral, direct factor Xa inhibitor – are not affected by aspirin // J. Clin. Pharmacol.– 2006.– Vol. 46.– P. 981–990.
51. Lane D.A., Lip G.Y.H. Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in non-valvular atrial fibrillation // Circulation.– 2012.– Vol. 126.– P. 860–865.
52. Lassen M.R., Raskob G.E., Gallus A. et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial // Lancet.– 2010.– Vol. 375.– P. 807–815.
53. Lassen M.R., Raskob G.E., Gallus А. et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement // New Engl. J. Med.– 2009.– Vol. 361.– P. 594–604.
54. Lip G.Y.H., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation // Chest.– 2010.– Vol. 137.– P. 263–272.
55. Lohrmann J., Becker R.C. New anticoagulants – the path from discovery to clinical practice // New Engl. J. Med.– 2008.– Vol. 358.– P. 2827–2829.
56. Lowe B.S., Chung M.K., Klein A.L. Antithrombotic treatment and cardioversion of patients with atrial fibrillation // Atrial Fibrillation – From Bench to Bedside / Ed. by A. Natale, J. Jalife.– Totowa, N.J.: Humana Press, 2008.– Ch.12.– P. 169–184.
57. Mant J., Hobbs F.D., Fletcher K. et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial // Lancet.– 2007.– Vol. 370.– P. 493–503.
58. Medi C., Hankey G.J., Freedman S.B. Stroke risk and antithrombotic strategies in atrial fibrillation // Stroke. – 2010.– Vol. 41, № 11.– P. 2705–2713. 
59. Mega J.L. A New era for anticoagulation in AF // New Engl. J. Med.– 2011.– Vol. 365, № 11.– P. 1052–1054.
60. Mega J.L., Braunwald E., Mohanavelu S. et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial // Lancet.– 2009.– Vol. 374.– P. 29–38.
61. Montoro-Garcia S., Marin F., Lip G.Y.H. Thrombogenesis in lone atrial fibrillation: a role for soluble P-selectin? // Europace.– 2011.– Vol. 13.– P. 3–4.
62. Oldgren J., Budaj A., Granger C.B. et al. Dabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial // Eur. Heart J.– 2011.– Vol. 32, № 22.– P. 2781–2789.
63. Olsson S.B., Rasmussen L.H., Tveit A. et al. Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation // Thromb. Haemost.– 2010.– Vol. 103.– P. 604–612.
64. Park J.H., Joung B., Son N.H. et al. The electroanatomical remodelling of the left atrium is related to CHADS2/CHA2DS2VASc score and events of stroke in patients with atrial fibrillation // Europace.– 2011.– Vol. 13.– P. 1541–1549.
65. Pisters R., Lane D.A., Marin F. et al. Stroke and thromboembolism in atrial fibrillation // Circulation J.– 2012.– Vol. 76.– P. 2289–2304.
66. Pisters R., Lane D.A., Nieuwlaat R. et al. A novel user friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey // Chest.– 2010.– Vol. 138, № 5.– P. 1093–1100.
67. Riva N., Lip G.Y.H. A new era for anticoagulation in atrial fibrillation. Which anticoagulant we choose for long-term prevention of thromboembolic complications in patients with atrial fibrillation? // Pol. Arch. Med. Wewn.– 2012.– Vol. 122, № 12.– P. 45–53.
68. ROCKET AF Study Investigators. Rivaroxaban – once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study // Amer. Heart J.– 2010.– Vol. 159.– P. 340–347.
69. Schulman S., Kearon C., Kakkar A.K. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism // New Engl. J. Med.– 2009.– Vol. 361.– P. 2342–2352.
70. Singer D.E., Albers G.W., Dalen J.E. et al. Antithrombotic therapy in atrial fibrillation // Chest.– 2008.– Vol. 133.– P. 546–592.
71. Stoddard M.F. Risk of thromboembolism in new onset or transient atrial fibrillation // Progr. Cardiovasc. Dis.– 1996.– Vol. 39.– P. 69–80.
72. Turpie A.G.G. New oral anticoagulants in atrial fibrillation // Eur. Heart J.– 2007.– Vol. 29.– P. 155–165.
73. Turpie A.G.G. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases // Arterioscler. Thromb. Vasc. Biol.– 2007.– Vol. 27.– P. 1238–1247.
74. VanRyn J., Stangier J., Haertter S. et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity // Thromb. Haemost.– 2010.– Vol. 103.– P. 1116–1127.
75. Velu S., Lip G.Y. Recent progress in antithrombotic therapy for atrial fibrillation // J. Atheroscler. Thromb. – 2011.– Vol. 18, № 4.– P. 257–273. 
76. Verheugt F.W.A. Advances in stroke prevention in atrial fibrillation: enhanced risk stratification combined with the newer oral anticoagulants // Clin. Cardiol.– 2013.– Vol. 36, № 6.– P. 312–322.
77. Waldo A.L. Anticoagulation: stroke prevention in patients with atrial fibrillation // Cardiol. Clin. – 2009.– Vol. 27, № 1.– P. 125–135.
78. Weijs B., Blaauw Y., Roger J. et al. Patient using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients // Eur. Heart J.– 2011.– Vol. 32.– P. 2555–2562.
79. You J.J., Singer D.E., Howard P. A. et al. Antithrombotic therapy for atrial fibrillation antithrombotic therapy and prevention of thrombosis. 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines // Chest.– 2012.– Vol. 141 (Suppl. 2).– P. 531–575.